Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million
Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.
Overview
Ian T. Clark, a Director at Guardant Health, Inc. (NASDAQ:GH), reported a sale of 14,180 shares of common stock on Aug. 4, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($158.92); post-transaction value based on Aug. 4, 2026 market close ($159.79).
Details
Guardant Health is a precision oncology company with a market capitalization of $21.4 billion, generating $1.2 billion in TTM revenue through its portfolio of liquid biopsy diagnostic tests. The company leverages advanced molecular analytics and comprehensive genomic profiling to establish a competitive moat in the high-growth oncology diagnostics market, though it remains in a net loss position as it scales operations and invests in research and development initiatives.
Source
Originally published at www.fool.com.